Analysts Anticipate BioPharmX Corporation (BPMX) Will Announce Earnings of -$0.01 Per Share

Brokerages expect BioPharmX Corporation (NASDAQ:BPMX) to report earnings of ($0.01) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for BioPharmX’s earnings. BioPharmX reported earnings per share of ($0.02) during the same quarter last year, which indicates a positive year-over-year growth rate of 50%. The company is scheduled to announce its next earnings report on Thursday, June 6th.

On average, analysts expect that BioPharmX will report full year earnings of $0.05 per share for the current year, with EPS estimates ranging from ($0.04) to $0.13. For the next fiscal year, analysts anticipate that the firm will post earnings of ($0.03) per share. Zacks’ EPS averages are an average based on a survey of analysts that cover BioPharmX.

BioPharmX (NASDAQ:BPMX) last released its quarterly earnings results on Thursday, March 14th. The company reported ($0.01) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.01. The company had revenue of $0.01 million for the quarter.

BPMX stock remained flat at $$0.07 during mid-day trading on Friday. The company’s stock had a trading volume of 107,799 shares, compared to its average volume of 8,493,744. BioPharmX has a fifty-two week low of $0.05 and a fifty-two week high of $0.29.

BioPharmX Company Profile

BioPharmX Corporation, a specialty pharmaceutical company, develops and commercializes novel prescription and over-the-counter (OTC) products that address dermatology and women's health markets. The company offers VI2OLET, an OTC molecular iodine dietary supplement that addresses cyclic breast discomfort, as well as alleviates the symptoms of fibrocystic breast condition (FBC).

Featured Article: What is the QQQ ETF?

Get a free copy of the Zacks research report on BioPharmX (BPMX)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for BioPharmX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioPharmX and related companies with's FREE daily email newsletter.